Metabolic Syndrome Increases Operative Mortality in Patients Undergoing Coronary Artery Bypass Grafting Surgery  by Echahidi, Najmeddine et al.
D
u
r
m
a
F
C
C
h
H
t
s
D
M
f
O
2
Journal of the American College of Cardiology Vol. 50, No. 9, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PMetabolic Syndrome
Metabolic Syndrome Increases
Operative Mortality in Patients Undergoing
Coronary Artery Bypass Grafting Surgery
Najmeddine Echahidi, MD,* Philippe Pibarot, DVM, PHD, FACC, FAHA,*
Jean-Pierre Després, PHD, FAHA,† Jean-Marc Daigle MSC,‡ Dania Mohty, MD,*
Pierre Voisine, MD, Richard Baillot, MD, Patrick Mathieu, MD
Quebec, Canada
Objectives The aim of this study was to determine the impact of the metabolic syndrome (MS) on operative mortality after
a coronary artery bypass grafting surgery (CABG).
Background Diabetes and obesity are highly prevalent among patients undergoing CABG. However, it remains unclear
whether these factors have a significant impact on operative mortality after this procedure. We hypothesized
that the metabolic abnormalities associated with MS could negatively influence the operative outcome of CABG
surgery.
Methods We retrospectively analyzed the data of 5,304 consecutive patients who underwent an isolated CABG procedure
between 2000 and 2004. Of these 5,304 patients, 2,411 (46%) patients met the National Cholesterol Education
Program–Adult Treatment Panel III criteria for MS. The primary end point was operative mortality.
Results The operative mortality after CABG surgery was 2.4% in patients with MS and 0.9% in patients without MS (p 
0.0001). The MS was a strong independent predictor of operative mortality (relative risk 3.04 [95% confidence
interval (CI) 1.73 to 5.32], p  0.0001). After adjusting for other risk factors, the risk of mortality was increased
2.69-fold (95% CI 1.43 to 5.06; p  0.002) in patients with MS and diabetes and 2.36-fold (95% CI 1.26 to
4.41; p  0.007) in patients with MS and no diabetes, whereas it was not significantly increased in the patients
with diabetes and no MS.
Conclusions This is the first study to report that MS is a highly prevalent and powerful risk factor for operative mortality in
patients undergoing a CABG surgery. Thus, interventions that could contribute to reduce the prevalence of MS in
patients with coronary artery disease or that could acutely modify the metabolic perturbations of MS at the time
of CABG might substantially improve survival in these patients. (J Am Coll Cardiol 2007;50:843–51) © 2007
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.075t
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diabetes and obesity are highly prevalent in the population
ndergoing coronary artery bypass grafting (CABG). These
isk factors have been shown to have a significant impact on
orbidity after CABG (1–9). Metabolic syndrome (MS) is
cluster of metabolic perturbations largely resulting from
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ontreal, Quebec, Canada. Dr. Mohty receives a postdoctoral fellow scholarship
rom the training program on obesity of the Canadian Institutes of Health Research,
ttawa, Ontario, Canada.a
Manuscript received December 8, 2006; revised manuscript received April 12,
007, accepted April 24, 2007.he presence of abdominal obesity, which is associated with
n increased risk of type 2 diabetes and cardiovascular
isease (10,11).
The MS largely results from the accumulation of
bdominal fat and is characterized by insulin resis-
ance, hypertriglyceridemia, low high-density lipoprotein
HDL) cholesterol, and a pro-inflammatory and pro-
hrombotic state (12). The prevalence of MS has been
stimated to reach approximately 35% to 40% of the
opulation of industrialized countries (13). We hypoth-
sized that the pro-inflammatory and pro-thrombotic
eatures of MS could adversely affect the operative
utcome in patients undergoing the CABG procedure.
he objective of this retrospective study was thus to
etermine the impact of MS on operative mortality after
CABG surgery.
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Patient population. The preop-
erative and operative data of all
patients undergoing a cardiac
surgery in our institution were
prospectively collected and entered
in a computerized database. Post-
operative complications were also
recorded prospectively by trained
personnel composed of a research
nurse and a medical archivist. All
major adverse events were pro-
spectively validated by an experi-
enced cardiac surgeon according
o standard definitions. A fasting plasma lipid profile
including total cholesterol, low-density lipoprotein [LDL]
holesterol, HDL cholesterol, and triglyceride levels) and
lood pressure were also assessed in the resting state.
urthermore, waist circumference was systematically mea-
ured since January 2000. For this study, we included
atients who underwent a first CABG operation without
ssociated procedures between January 2000 and December
004. During this period, 5,829 patients underwent a first
ABG procedure, and from this group the data concerning
S status were available for 5,304 patients, which con-
titute the population of this study. The missing data
egarding the National Cholesterol Education Program–
dult Treatment Panel III (NCEP-ATPIII) criteria for
he 525 patients not included in the present analyses
ere, in part, explained by the fact that a large proportion
53%) of these patients underwent operation on an
mergency basis, thus allowing less time before surgery to
cquire the relevant information.
perative technique. During the study period, a team of
2 surgeons performed the CABG procedures. Anesthetic
nd surgical techniques were standardized for all patients.
atients were operated through a mid-sternotomy. In pa-
ients operated with cardiopulmonary bypass (93.7% of the
otal patients), moderate systemic hypothermia (32°C) and
ntermittent antegrade cold blood cardioplegia were used.
roximal anastomoses were performed routinely on a side
iting clamp. In patients operated off-pump (6.3%), coro-
ary stabilization was obtained with a pressure type stabil-
zer doing the distal anastomoses first (14). After surgery,
atients were transferred to the intensive care unit. They
ere extubated as soon as they met the following criteria:
ormothermia, consciousness, hemodynamic stability, and
o significant bleeding.
linical and laboratory data. Clinical data included his-
ory of smoking and documented diagnoses of hypertension
patients receiving antihypertensive medications or having
nown but untreated elevated blood pressure [130/85 mm
g]), diabetes (patients with established diagnoses currently
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
MI  myocardial infarction
MS  metabolic syndrome
RR  relative riskeceiving oral hypoglycemic medication or insulin), obesity bbody mass index 30 kg/m2), and renal failure (creatinine
150 mol/l).
dentification of patients with MS. The clinical identifi-
ation of patients with the features of MS was based on the
odified criteria proposed by the NCEP-ATPIII (15).
atients were considered to have MS when 3 of the 5
ollowing criteria were present: 1) waist circumference102
m in men and88 cm in women; 2) fasting glycemia6.1
mol/l; 3) triglycerides 1.69 mmol/l; 4) HDL cholesterol
1.04 mmol/l in men and 1.29 mmol/l in women; and
) hypertension.
nd points of the study. The primary end point was
perative mortality defined as death from any cause within
0 days after operation or any interval if the patient was not
ischarged. The secondary end point was morbidity occur-
ing during the hospital stay period. Perioperative myocar-
ial infarction (MI) was defined as the appearance of a new
-wave on the electrocardiogram or a rise in the creatine
inase-myocardial band (CK-MB) level 75 g/l during
he hospital stay period. The CK-MB levels were monitored
uring the first 48 h after surgery, whereas electrocardio-
rams were examined daily. A postoperative stroke was
dentified when a new central neurologic deficit was de-
ected and lasted for more than 24 h or detected with
maging techniques when the patient died within the 24-h
eriod after operation. The criterion for postoperative renal
ailure was an increase of at least 50% of the baseline serum
reatinine level. The criterion for postoperative septicemia
as the presence of a positive blood culture. A mediastinitis
as diagnosed when a deep sternal infection was present,
ecessitating an opening of the wound with excision of
issue and treatment with antibiotics. The criteria for
neumonia included a positive culture of the sputum asso-
iated with a radiological infiltration.
tatistical analysis. Continuous variables were expressed
s mean  SD, whereas categorical data were expressed as
ercentages. For continuous variables, values were com-
ared by using 2-sample t tests for independent samples.
ifferences in proportion were compared with a chi-square
est or Fisher exact test, as appropriate. The association
etween operative mortality and the different risk factors
as first examined by calculating relative risks (RRs) with
ge-adjusted univariate logistic analysis. A stepwise lo-
istic regression was then used to develop a multivariate
odel that identified the best set of predictors of oper-
tive mortality. The multivariate models were con-
tructed from the Hosmer-Lemeshow approach. The
ariables listed in Table 1 were first tested on univariate
nalysis, and those with a p value 0.25 were entered in
he multivariate analyses. Backward analyses allowed
limination of the less significant variables. To detect a
ossible provider effect, the 12 surgeons who had per-
ormed the surgeries were entered as a covariable into the
ultivariate model.
To eliminate covariate differences that might lead toiased estimates of MS effect, a propensity score adjust-
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August 28, 2007:843–51 Metabolic Syndrome and CABGent was also used (16). Propensity score was computed
ith logistic regression with the dependent variable being
S and the independent variables (covariates) being
ender, peripheral vascular disease, chronic obstructive
ulmonary disease, preoperative renal failure, preopera-
ive MI, and preoperative stroke. We estimated the
djusted relative operative mortality risk associated with
reoperative and Operative Data of Patients Undergoing CABG, Wi
Table 1 Preoperative and Operative Data of Patients Undergoin
All Patients
(n  5,304)
Age, yrs 64 10
Female patients 23.3%
Body mass index, kg/m2 28 5
Waist circumference, cm 100 13
Risk factors and concomitant diseases
Underweight (18.5 kg/m2) 0.7%
Normal weight (18.5–24.9 kg/m2) 26.1%
Overweight (25.0–29.9 kg/m2) 44.5%
Obesity (30 kg/m2) 28.7%
Active smokers 18.7%
Hypertension 64.3%
Diabetes mellitus 31.4%
HDL cholesterol, mmol/l 1.12 0.32
LDL cholesterol, mmol/l 2.31 0.87
Triglycerides, mmol/l 1.67 1.01
Fasting glycemia, mmol/l 6.16 2.04
Microalbuminuria 20 mg/l 29.5%
Parsonnet score 20 8.1%
Functional CCS class IV* 17.3%
Peripheral vascular disease 15.6%
COPD 10.7%
Renal failure (creatinine 150 mol/l) 6.2%
Left ventricular ejection fraction 40% 8.0%
Left main stenosis 50% 47.1%
2-vessel disease 37.1%
3-vessel disease 50.1%
Previous cardiovascular events
MI 49.0%
MI within 7 days before surgery 7.2%
Stroke 4.8%
Atrial fibrillation 4.1%
Previous coronary artery dilation/stenting 12.4%
Operative data
Operative status
Elective 70.1%
Urgent 29.3%
Emergent 0.6%
Cardiopulmonary bypass time (min) 75 23
Aortic cross-clamp time (min) 49 18
Volume of cardioplegia (ml/min AoX) 40 19
Mammary artery graft 92.8%
Off-pump bypass surgery 6.3%
Operative mortality 1.6%
ean  SD for continuous variables are shown. *Functional class for angina as defined by the Ca
AoX aortic cross-clamp time; CABG coronary artery bypass grafting; COPD chronic obstru
nfarction.S by using the propensity score as a covariate into the Codel. Propensity-based matching with a conditional
ogistic model was also used to select control patients who
re similar to patients with MS with respect to propensity
core and other covariates such as age, discarding un-
atched individuals. A p value 0.05 was considered
ignificant. All the statistical analyses were per-
ormed with SAS version 9.1 (SAS Institute, Cary, North
d Without Metabolic Syndrome
BG, With and Without Metabolic Syndrome
Metabolic Syndrome
p Value
Absent
(n  2,893)
Present
(n  2,411)
64 10 65 10 0.39
16.1% 31.9% 0.0001
26 4 30 5 0.0001
96 11 106 12 0.0001
1.1% 0.3% 0.0002
37.1% 12.9% 0.0001
47.9% 40.4% 0.0001
13.9% 46.5% 0.0001
19.5% 17.8% 0.11
47.0% 85.1% 0.0001
16.6% 49.0% 0.0001
1.21 0.32 1.00 0.27 0.0001
2.33 0.84 2.29 0.90 0.09
1.30 0.61 2.11 1.20 0.0001
5.54 1.32 6.91 2.45 0.0001
21.3% 33.5% 0.0001
5.0% 11.8% 0.0001
16.7% 18.0% 0.24
13.6% 18.0% 0.0001
10.3% 11.2% 0.28
4.4% 8.4% 0.0001
8.0% 7.9% 0.91
48.1% 45.9% 0.31
36.9% 37.4% 0.68
49.0% 51.4% 0.08
49.2% 48.9% 0.85
7.7% 6.7% 0.38
4.3% 5.5% 0.038
4.4% 3.8% 0.23
12.2% 12.8% 0.52
70.3% 70.0% 0.85
29.2% 29.4% 0.87
0.6% 0.6% 0.89
74 23 76 23 0.0007
48 17 50 18 0.005
39 12 41 25 0.20
92.1% 91.4% 0.38
6.2% 6.4% 0.68
0.9% 2.4% 0.0001
Cardiovascular Society (CCS).
lmonary disease; HDL high-density lipoprotein; LDL low-density lipoprotein; MImyocardialth an
g CA
nadianarolina).
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atient characteristics. During the study period, a total of
,304 patients for whom MS status was known underwent
first isolated CABG procedure. Of those patients 2,411
46%) patients met the criteria for MS. The baseline
haracteristics for the different groups are presented in
able 1, and the distribution of the NCEP-ATPIII criteria
sed to define MS is presented in Table 2. When compared
ith patients without MS, those with MS had a higher
roportion of women, a higher prevalence of hypertension,
iabetes, obesity, peripheral vascular disease, renal failure,
nd a previous history of stroke (Table 1). In addition
atients with MS had, as expected, higher fasting glycemia,
igher plasma triglyceride levels, lower HDL cholesterol
oncentrations, and a higher prevalence of microalbumin-
ria. The proportion of patients with a Parsonnet score
20, evaluating the operative risk, was significantly higher
n patients with MS. The average volume of cardioplegia
eceived per minute of aortic cross-clamp time was similar
n both groups.
ortality and morbidity. Overall, operative mortality was
.6%, studying the entire cohort of patients included in this
tudy. The operative mortality was markedly higher (p 
.0001) in patients having MS (2.4%) than in those without
S (0.9%) (Table 1). When adjusted for age, MS was
ssociated with a 2.8-fold increase in the risk of mortality
Table 3). There was no cumulative effect with respect to
he number of NCEP-ATPIII components of MS (Fig. 1).
mong the other risk factors, age75 years, female gender,
eing underweight (body mass index 18.5 kg/m2), hyper-
ension, fasting glycemia 6.1 mmol/l, peripheral vascular
isease, chronic obstructive pulmonary disease, renal failure,
eft ventricular ejection fraction40%, history of MI within
days before surgery, stroke, urgent or emergent operative
tatus, and cardiopulmonary bypass time 120 min were
Prevalence and Distribution of the NCEP-ATPIIIM taboli Sy rome in Patients With and Witho
Table 2 Prevalence and Distribution of the NMetabolic Syndrome in Patients Wi
All Patient
(n  5,304
Waist circumference 102 cm in men
and 88 cm in women
49.2%
Fasting glycemia 6.1 mmol/l 34.9%
Triglycerides 1.69 mmol/l 37.4%
HDL cholesterol 1.04 mmol/l in men
and 1.29 mmol/l in women
52.3%
Hypertension 64.3%
0 criteria 431 (8.1%
1 criteria 1,208 (22.8%
2 criteria 1,254 (23.6%
3 criteria 1,369 (25.8%
4 criteria 783 (14.8%
5 criteria 259 (4.9%
HDL  high-density lipoprotein; NCEP-ATPIII  National Cholesterol Eignificantly associated with higher operative mortality (Ta- ile 3). The stratification of the analysis according to gender
evealed that the impact of MS on mortality was comparable
etween men (2.60 [95% confidence interval (CI) 1.44 to
.70] [p  0.0015]) and women (2.39 [95% CI 1.03 to
.54] [p  0.04]).
On multivariate analysis, MS was independently associ-
ted with increased operative mortality with an RR of 3.04
95% CI 1.73 to 5.32 [p  0.0001]) (model #1, Table 4).
he other independent risk factors for mortality were: age
75 (RR 2.72), being underweight (RR 11.07), preopera-
ive renal failure (RR 2.44), cardiopulmonary bypass time
120 min (RR 5.65), and urgent/emergent operative status
RR 2.18 and 5.54, respectively). The surgeon variable was
ot independently associated with increased mortality,
hich further supports the adequacy of the standardization
f surgical technique among the different surgeons who
erformed CABG procedures. Diabetes, hypertension, obe-
ity, as well as the 5 components of MS included in the
efinition of the NCEP-ATPIII were not independently
ssociated with increased operative mortality. When the 5
omponents of MS (included as dichotomous variables) and
S were entered in a sequential manner in a multivariate
odel (model #2) including other covariates, MS remained
ndependently associated with operative mortality: RR
.06 (95% CI 1.51 to 10.9; p  0.005). When entering
S components as continuous variables instead of di-
hotomous, MS remained independently associated with
perative mortality: RR 2.8 (95% CI 1.31 to 5.97;
 0.008).
The MS was associated with higher mortality rates in
oth nondiabetic (2.04% vs. 1.00%; p  0.014) and diabetic
2.71% vs. 0.21%; p  0.0001) patients. We constructed a
hird multivariate model (model #3) in which we analyzed
he interaction between MS and diabetes with adjustment
or other covariates. In this model, the risk of mortality was
ria foretabolic Syndrome
-ATPIII Criteria for
d Without Metabolic Syndrome
Metabolic Syndrome
p Value
Absent
(n  2,893)
Present
(n  2,411)
24.0% 79.1% 0.0001
16.1% 57.5% 0.0001
14.3% 65.3% 0.0001
30.4% 78.6% 0.0001
47.0% 85.1% 0.0001
431 (14.9%) 0
1,208 (41.8%) 0
1,254 (43.3%) 0
0 1,369 (56.8%)
0 783 (32.5%)
0 259 (10.7%)
n Program–Adult Treatment Panel III.Criteut M
CEP
th an
s
)
)
)
)
)
)
)ncreased by 2.69-fold (95% CI 1.43 to 5.06; p  0.002) in
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August 28, 2007:843–51 Metabolic Syndrome and CABGatients with MS and diabetes and 2.36-fold (95% CI 1.26
o 4.41; p  0.007) in patients with MS and no diabetes
Fig. 2). However, the mortality risk was not significantly
ncreased in patients with diabetes and no MS: 0.19-fold
95% CI 0.03 to 1.4; p  0.11).
To further corroborate the results of the multivariate
ogistic regression models presented earlier, we performed a
ropensity score analysis. The propensity score was calcu-
ated to adjust for covariate differences between MS and no
S groups. After adjusting for the propensity score, age,
ody mass index, emergent/urgent operation, previous
troke, peripheral vascular disease, and renal failure, MS
emained a strong independent predictor of operative mor-
ality: RR 2.98 (95% CI 1.72 to 5.16; p  0.0001). The RR
Univariate Analysis of Potential Risk Factors for
Table 3 Univariate Analysis of Potential Ris
Risk Factors
Age 75 yrs
Female gender
Metabolic syndrome (NCEP-ATPIII)
Active smoker
Diabetes mellitus
BMI
Normal weight (BMI 18.5–24.9)
Underweight (BMI 18.5)
Overweight (BMI 25.0–29.9)
Obese (BMI 30.0)
Microalbuminuria 20 mg/l
Functional CCS class IV
Peripheral vascular disease
COPD
Renal failure
Left ventricular ejection fraction 40%
Left main stenosis 50%
NCEP-ATPIII criteria
Waist circumference (102 cm in men and 88 cm in w
Fasting glycemia 6.1 mmol/l
Triglycerides 1.69 mmol/l
HDL cholesterol (1.04 mmol/l in men and 1.29 mmo
Hypertension
Previous cardiovascular events
MI
MI within 7 days before surgery
Stroke
Atrial fibrillation
Previous coronary artery dilatation/stenting
Operative variables
Operative status
Elective
Urgent
Emergent
Mammary artery graft
Off-pump bypass surgery
Cardiopulmonary bypass time 120 min
BMI  body mass index; CI  confidence interval; other abbreviations.53 (95% CI 1.44 to 4.44; p  0.0012) was also similar chen using a conditional logistic model with propensity-
ased matching cohort.
Table 5 presents the causes of death. The most common
ause of death was cardiac in 57.3% of the cases. There
as no significant difference between MS and non-MS
atients with regard to the distribution of cause of death. There
ere more postoperative stroke (2.3% vs. 1.4%; p  0.014),
enal failure (12.4% vs. 6.8%; p  0.0001), and infectious
omplications in patients with MS than in those without MS
Table 6). Among infectious complications, patients with MS
ad more pneumonia (2.0% vs. 1.2%; p  0.017) and medi-
stinitis (2.0% vs. 0.7%; p  0.0001). After adjustment with
he propensity score and other covariates, MS remained inde-
endently associated with the following postoperative compli-
rative Mortality
tors for Operative Mortality
Age-Adjusted
Relative Risk 95% CI p Value
3.40 2.16–5.37 0.0001
1.97 1.25–3.11 0.003
2.77 1.72–4.45 0.0001
1.11 0.60–2.04 0.75
1.49 0.96–2.33 0.078
1.00 Referent —
10.28 3.83–27.63 0.0001
0.89 0.51–1.55 0.68
1.10 0.61–2.00 0.75
1.55 0.59–4.04 0.37
1.54 0.92–2.57 0.10
2.32 1.44–3.75 0.0006
2.21 1.30–3.75 0.003
3.44 1.97–5.99 0.0001
2.10 1.12–3.93 0.021
1.37 0.74–2.52 0.31
) 1.76 1.05–2.94 0.33
1.96 1.26–3.05 0.003
1.14 0.72–1.80 0.57
omen) 1.29 0.82–2.01 0.27
2.34 1.33–4.12 0.003
1.36 0.87–2.13 0.18
4.03 1.93–8.41 0.0002
2.82 1.46–5.42 0.002
1.40 0.60–3.29 0.445
1.21 0.63–2.30 0.57
1.00 Referent
2.50 1.60–3.91 0.0001
6.37 1.44–28.15 0.015
0.39 0.23–0.68 0.0008
0.49 0.15–1.57 0.23
5.25 2.70–10.22 0.0001
ables 1 and 2.Ope
k Fac
omen
l/l in wations: stroke, RR 1.61 (95% CI 1.03 to 2.53; p  0.037);
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Metabolic Syndrome and CABG August 28, 2007:843–51enal failure, RR 2.20 (95% CI 1.75 to 2.78; p  0.0001);
ediastinitis, RR 2.93 (95% CI 1.60 to 5.37; p 0.0003); and
neumonia, RR 1.79 (95 CI 1.09 to 2.95; p  0.022).
he incidence of perioperative MIs was similar in both
roups. In addition, the magnitude of myocardial tissue
amage as measured with the maximum postoperative
ise of CK-MB was s imi lar in both groups
41  78 g/ml in MS patients vs. 41  68 g/ml in
on-MS patients [p  0.91]). Moreover, there was no
ignificant difference between groups with regard to the
aximum postoperative rise of troponin I that was
easured in 4,573 patients of the cohort (MS: 31  65
g/l vs. no MS: 31  66 g/l [p  0.75]).
Figure 1 The Effect of the Number of Metabolic Syndrome Com
The operative mortality risk was adjusted for age and gender, and the group with n
(NCEP-ATPIII) was used as the referent.
Multivariable-Adjusted Relative Risk of Operativ
Table 4 Multivariable-Adjusted Relative Risk
Risk Factors R
Age 75 yrs
Female gender
Metabolic syndrome (NCEP-ATPIII)
Body mass index
Normal weight
Underweight
Overweight
Obese
Previous stroke
Peripheral vascular disease
Renal failure
Operative status
Elective
Urgent
Emergent
Cardiopulmonary bypass time 120 minCI  confidence interval; NCEP-ATPIII  National Cholesterol Education Progiscussion
he most important contribution of this study was to
emonstrate that MS is a strong and independent predictor
f operative morbidity and mortality after a CABG surgery.
hese findings have major clinical implications given that:
) MS was found to be highly prevalent in our population of
atients submitted to a surgical revascularization; and 2) MS
s a potentially preventable or modifiable risk factor. In the
eneral population, MS has been reported to reach up to
5% of the population, whereas in our study 46% of the
atients undergoing CABG had MS. This finding is
onsistent with previous studies showing a similar prev-
nts on Operative Mortality Risk
ponent of the National Cholesterol Education Program–Adult Treatment Panel III
rtality
perative Mortality
e Risk 95% CI p Value
72 1.64–4.50 0.0001
59 0.96–2.62 0.070
04 1.73–5.32 0.0001
00 Referent —
07 3.60–34.01 0.0001
71 0.39–1.28 0.26
55 0.80–3.00 0.19
01 0.98–4.15 0.058
66 0.97–2.84 0.064
44 1.30–4.55 0.005
00 Referent —
18 1.36–3.49 0.001
54 1.18–26.11 0.03
65 2.82–11.33 0.0001pone
o come Mo
of O
elativ
2.
1.
3.
1.
11.
0.
1.
2.
1.
2.
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2.
5.
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August 28, 2007:843–51 Metabolic Syndrome and CABGlence of MS among patients with coronary artery disease
CAD) (17).
omparison with previous studies. Whereas diabetes and
besity have been associated with increased adverse periop-
rative events after a CABG, previous studies have not
ttempted to delineate the role of MS on the operative
ortality. Obesity or diabetes have been investigated in
ultiple studies and have been generally associated with an
ncreased operative morbidity (2,3). Although some studies
ave documented an increased operative mortality after
ABG in diabetic patients, others have not found such an
xcess mortality rate in this population (3–5). As opposed to
S, diabetes or obesity per se were not found to be
ndependent predictors of operative mortality in our study.
iabetic patients with MS had a markedly increased risk of
perative mortality, whereas those without MS were not at
igher risk. The effect of MS has not been taken into
ccount in previous studies (3–9), which might, at least in
art, explain the conflicting results obtained with regard to
Figure 2 Adjusted Relative Risk for Operative
Mortality According to MS and Diabetes
The relative risk was adjusted for age and other covariates, and the group with
no metabolic syndrome (MS) and no diabetes was used as the referent. The
error bars represent the 95% confidence interval.
erioperative Cause of Mortality for Patientsndergoing CABG According to Metabolic Syndrometatus
Table 5
Perioperative Cause of Mortality for Patients
Undergoing CABG According to Metabolic
Syndrome Status
Metabolic Syndrome
Cause All Patients Absent Present p Value
Cardiac 47 (57.3%) 13 (52.0%) 34 (59.6%) 0.52
Neurologic 11 (13.4%) 5 (20.0%) 6 (10.5%) 0.14
Septicemia 6 (7.3%) 2 (8.0%) 4 (7.0%) 0.34
Respiratory 6 (7.3%) 2 (8.0%) 4 (7.0%) 0.34
Multiple system
failure
4 (4.9%) — 4 (7.0%) —
Renal 1 (1.2%) — 1 (1.8%) —
Vascular 1 (1.2%) — 1 (1.8%) —
Others 5 (7.3%) 2 (12.0%) 3 (5.3%) 0.32
Total 82 (100.0%) 25 (30.5%) 57 (69.5%) 0.0001eABG  coronary artery bypass grafting.he association between diabetes and operative mortality.
he results of the present study suggest that the metabolic
bnormalities associated with MS have a much greater
mpact on short-term outcome after CABG than isolated
iabetes does. These results are also consistent with a
revious report indicating that the prevalence of CAD is
elatively low in diabetic patients without MS whereas it is
arkedly increased among diabetic patients with MS,
uggesting that the metabolic perturbations associated with
S are key factors in the development of atherosclerosis
nd cardiovascular events (18).
The causes of death among patients with or without MS
ere similar and were predominantly of cardiac origin
ollowed by neurologic causes, which is in agreement with a
revious study (3). We found similar incidence of
nfectious-related death among patients with MS versus
hose without MS, as opposed to what has been reported in
iabetic patients (3). Nonetheless, MS patients had an
ncreased incidence of infectious complications after CABG
urgery. In addition, MS was independently associated with
n increased risk of postoperative stroke and renal failure.
owever, the incidence of perioperative MIs was similar
etween the patients with or without MS.
otential mechanisms responsible for the association
etween MS and operative mortality after CABG. The
S is characterized by a low-grade inflammatory state
ccompanied by increased circulating levels of inflammatory
ytokines (19). Different mechanisms contribute to this
ro-inflammatory state. Visceral adipocytes have been
hown to produce more interleukin-6 than their subcutane-
us counterparts, which in turn stimulates liver production
f C-reactive protein (20). Furthermore, increased circulat-
ng level of tumor necrosis factor-alpha has been docu-
ented in patients with MS (21). In addition, fat specific
roteins, or adipokines, are modulated by obesity. Patients
ith MS have reduced plasma adiponectin concentrations,
hereas leptin and resistin levels are elevated (22). As
pposed to leptin and resistin, which activate the immune
ystem, adiponectin inhibits the inflammatory activation of
he vascular wall largely through the inhibition of the
uclear factor kappa B pathway (23). Therefore, the pro-
nflammatory state associated with MS might contribute to
erioperative Complications After CABG
Table 6 Perioperative Complications After CABG
Metabolic Syndrome
p ValueComplications Absent Present
Perioperative MI 15.5% 16.3% 0.44
Stroke 1.4% 2.3% 0.014
Renal failure 6.8% 12.4% 0.0001
Pneumonia 1.2% 2.0% 0.017
Mediastinitis 0.7% 2.0% 0.0001
Septicemia 0.5% 0.8% 0.17
ABG  coronary artery bypass grafting; MI  myocardial infarction.xacerbate the systemic inflammatory response to cardiopul-
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he occurrence of related perioperative complications (24).
In addition to the production of numerous proteins with
mmunomodulatory activity, adipocytes also produce the
ro-thrombotic plasminogen activator inhibitor (PAI)-1,
hich is elevated in obese subjects (25). Hence, a pro-
hrombotic state, which is a frequent occurrence in the
ostoperative period of CABG, might be exacerbated in
atients with MS, thus explaining the increased incidence of
hrombo-embolic events in this population. In a midterm
ollow-up study, Yilmaz et al. (26) have reported that MS is
predictor of saphenous vein grafts occlusion after CABG.
n the present study, we have not detected an increased
ncidence of perioperative MI or myocardial tissue damage
n MS patients. However, perioperative MI is likely not
etermined by early graft occlusion but rather by factors
elated to myocardial protection strategies or unknown
actors, which could explain the absence of difference
etween patients with or without MS. Other factors, such as
n abnormal vasoactive response, might contribute in the
ostoperative period to hemodynamic instability. Indeed,
nsulin-resistant subjects are characterized by an altered
ndothelial-dependent vasodilation (27). Therefore, al-
hough speculative for the moment, loss of vasodilation,
ncreased vasospastic stimuli, and a pro-thrombotic state
ight all contribute to hemodynamic instability during the
arly postoperative period, which could contribute to the
orse outcome observed in patients with MS.
linical implications. We found that MS is a highly
revalent and powerful risk factor for operative mortality
fter CABG surgery, a finding that has major clinical
mplications. For instance, MS is a potentially preventable
nd modifiable condition that often goes undiagnosed and
ntreated. Given that: 1) a large number (approximately
00,000) of CABG procedures are performed each year
orldwide (5); 2) this procedure is associated with substan-
ial operative mortality (1% to 5%) (5,28); and 3) MS is
ighly prevalent (40% to 50%) in this population and is
ssociated with a 3-fold increase in mortality, it can be
stimated that a considerable number of deaths occurring
uring the perioperative period of CABG are directly
elated to MS. The identification of MS could thus be
seful to identify high-risk patients who would, otherwise,
ot be detected with the use of traditional risk factors.
ence, the integration of MS into the operative risk
lgorithms might contribute to improve risk stratification.
Considering that patients with CAD have a significant
ifetime risk to develop complications requiring CABG
urgery, secondary prevention in these patients could con-
ribute to markedly reduce the operative mortality associated
ith MS. In light of the results of this study, aggressive
reatment of the components of MS should be considered in
atients with known CAD not only to decrease the overall
isk of acute coronary events but also to reduce the operative
isk in the event a CABG surgery is required in these
atients. In this regard, it should be pointed out that many if the components of MS are not reversed by the pharma-
ological treatment of traditional risk factors. Indeed, the
harmacological agents (i.e., statins, angiotensin-converting
nzyme inhibitors, beta-blockers) that are most often used in
atients with CAD have no or little effect on the metabolic
erturbations associated with MS. Furthermore, such ap-
roaches fail to target a central factor in the etiology of the
revalent form of MS (i.e., visceral obesity). Thus, the treat-
ent of the components of MS requires aggressive changes in
ifestyle habits such as increasing physical activity and imple-
enting dietary changes leading to weight reduction and loss
f visceral fat (29). In addition to lifestyle modifications, newer
harmacologic approaches (30) that specifically target some of
he key causal mechanisms of MS might also be considered as
ecoming part of the secondary prevention strategy in patients
ith CAD. Secondary prevention should also become an
mportant consideration in patients with MS who already
nderwent CABG, given that these patients are at risk for graft
cclusion (26) and thus re-operation. The aggressive treatment
f MS with the use of behavioral or pharmacological ap-
roaches might thus contribute to substantially reduce opera-
ive morbidity and mortality in these patients at the time of
e-operation.
In contrast, it remains to be determined whether it is
ossible to acutely modify some of the components of MS
n the pre- and/or perioperative period in patients planned
or CABG surgery and whether these modifications are able
o significantly reduce operative risk associated with MS. In
articular, it would seem difficult to modify the central
omponent of MS (i.e., the visceral adiposity) within a very
hort period of time. Nonetheless, it is possible that some of
he metabolic perturbations linked to visceral obesity might
e modifiable in the short term. To this effect, it has recently
een demonstrated that a tight control of perioperative
lycemia might improve operative outcomes in patients with
iabetes (31). Further studies are necessary to determine
hether perioperative glycemia control (31) or other acute
harmacological interventions might be successful to reduce
perative risk in MS patients planned for CABG surgery
30,32). Further prospective studies are needed to under-
tand the key mechanisms that are responsible for the
ncreased operative mortality after CABG in patients with
S. This new knowledge could pave the way to new
harmacologic therapy able to acutely modify the operative
isk associated with MS.
tudy limitations. The study was retrospective in nature.
owever, all the data including the complications were
rospectively collected by trained personnel. Major postop-
rative adverse events were also prospectively validated by an
xperienced cardiac surgeon according to standard defini-
ions. Several crucial plasma metabolic markers (e.g., insu-
inemia, inflammatory markers, PAI-1) were not measured
n this study. It was thus not possible to investigate the
otential mechanisms responsible for the significant and
ndependent association between MS and operative mortal-
ty. Patients with MS had more comorbidity. Consistently,
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August 28, 2007:843–51 Metabolic Syndrome and CABGheir operative risk assessed with the Parsonnet score was
igher, confirming the fact that this population is at higher
perative risk. One could thus argue that confounding variables
ight have contributed to the association observed between
S and mortality. However, when adjusting for all the
eported risk factors associated with poor outcome after
ABG, MS remained a strong and independent predictor for
perative mortality. In addition, propensity analysis has been
sed to reduce the effect of potential confounding variables,
nd the result of this analysis has confirmed the strong and
ndependent association of MS with operative mortality. These
esults therefore support the usefulness of the identification of
S for operative risk stratification before CABG surgery.
onclusions
his is the first study to report that MS is a strong and
ndependent risk factor for operative mortality after CABG
urgery. Given that MS is a frequent and modifiable risk factor,
he elaboration of prospective strategies focusing on the ag-
ressive treatment of its components could possibly contribute
o reduce operative mortality in patients undergoing surgical
oronary revascularization. Additional studies are warranted: 1)
o elucidate the mechanisms that are responsible for the
ssociation between MS and CABG operative mortality; and
) to identify the components of MS that should be considered
s new therapeutic targets in patients with CAD and especially
hose who are planned for CABG.
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